Results of the SORAYA study show conjugate therapy produced remissions in one-third of patients with drug-resistant ovarian cancer
Dana-Farber Cancer InstituteIn an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments. Mirvetuximab soravtansine was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in November 2022.